Humana (NYSE:HUM) Price Target Raised to $344.00

Humana (NYSE:HUM) had its price objective hoisted by investment analysts at Barclays from $180.00 to $344.00 in a research report issued on Tuesday,MarketScreener reports. Barclays‘s target price suggests a potential upside of 12.93% from the company’s current price.

A number of other analysts also recently issued reports on HUM. Wolfe Research downgraded shares of Humana from a “strong-buy” rating to a “peer perform” rating in a report on Wednesday, May 20th. Seaport Research Partners downgraded shares of Humana to a “neutral” rating in a research report on Wednesday, May 20th. Robert W. Baird cut their price target on shares of Humana from $264.00 to $205.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Piper Sandler restated a “neutral” rating and set a $254.00 price objective (up from $182.00) on shares of Humana in a research note on Wednesday, May 13th. Finally, Royal Bank Of Canada raised their price objective on Humana from $189.00 to $246.00 and gave the company a “sector perform” rating in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $270.48.

Humana Price Performance

HUM stock opened at $304.61 on Tuesday. The stock has a 50-day moving average price of $221.01 and a two-hundred day moving average price of $227.45. The stock has a market cap of $36.57 billion, a PE ratio of 32.58, a price-to-earnings-growth ratio of 2.86 and a beta of 0.68. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana has a 1 year low of $163.11 and a 1 year high of $315.66.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The company had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the company posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts forecast that Humana will post 9.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Revolve Wealth Partners LLC bought a new position in shares of Humana in the fourth quarter valued at about $202,000. Woodline Partners LP boosted its holdings in shares of Humana by 460.0% during the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after acquiring an additional 8,372 shares during the period. Sivia Capital Partners LLC grew its position in shares of Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after purchasing an additional 452 shares during the last quarter. Cresset Asset Management LLC increased its stake in shares of Humana by 10.3% during the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock worth $581,000 after purchasing an additional 222 shares during the period. Finally, WINTON GROUP Ltd grew its holdings in Humana by 58.5% in the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after buying an additional 879 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.